India Regulator Seeks Standardization of State-Level Drug Licensing Norms to Address Quality Disparities

India's Pharmaceutical Industry Sees Regulatory Shift with Uniform Licensing Guidelines

Key Developments:

• India's top drug regulator, the Drugs Controller General of India (DCGI), has issued a comprehensive guidance document mandating a dossier-based licensing system for all drug-manufacturing applications.
• The aim of this shift is to eliminate regional regulatory discrepancies and enforce a single, rigorous standard for drug approvals across the country.

Background:

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

India's $50 billion pharmaceutical industry has faced issues with uniformity in drug product licensing. The lack of a standardized checklist led to inconsistent evaluations of drug quality and safety, raising concerns about maintaining a singular quality standard in the country.

New Protocol:

The DCGI has introduced a dossier-based approach, where manufacturers must submit exhaustive data through the Online National Drugs Licensing System portal. This shift aims to address concerns regarding the quality, safety, and efficacy of drugs.

Key Features of the Guidance Document:

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

• A 41-item checklist split into two critical sections: Part A (administrative and facility-related details) and Part B (technical information about the drug).
• Manufacturers must submit technical information, including stability data, process validation data, and analytical method validation/verification data.
• The guidance document emphasizes the importance of standardized documentation to bring credibility and predictability to the regulatory system.

Industry Concerns:

Smaller companies may struggle to comply with the new guidelines, as they often lack the expensive machinery needed to run the required tests. Dr. G.L. Singhal, former drug controller of Haryana, noted that while big companies may comply, the rest of the industry may struggle to move beyond "paper compliance" to produce better drugs.